argenx SE
NASDAQ:ARGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Westlake Chemical Partners LP
NYSE:WLKP
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (7.1), the stock would be worth $843.85 (8% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.6 | $780.25 |
0%
|
| 3-Year Average | 7.1 | $843.85 |
+8%
|
| 5-Year Average | 7.1 | $842.88 |
+8%
|
| Industry Average | 6.2 | $736.15 |
-6%
|
| Country Average | 2.2 | $257.63 |
-67%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| NL |
|
argenx SE
NASDAQ:ARGX
|
41.2B USD | 6.6 | 37.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | -107.4 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 21.4 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 7.1 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 5.9 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 2.5 | 17.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 2.3 | 30.7 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.4B USD | 51.3 | 128.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.4 |
| Median | 2.2 |
| 70th Percentile | 4.4 |
| Max | 589.5 |
Other Multiples
argenx SE
Glance View
In a landscape where biotechnology companies tirelessly strive to transform scientific insight into therapeutic breakthroughs, argenx SE stands out with its innovative approach to harnessing the body's own immune system to address severe autoimmune diseases. Originating from the biopharmaceutical hubs of Belgium and the Netherlands, argenx was founded in 2008 and has since positioned itself at the forefront of immunology. At the heart of argenx's operations lies its proprietary SIMPLE Antibody™ technology platform, which engineers differentiated therapeutic antibodies. Guided by a deep understanding of disease biology, the company partners closely with academic institutions and leading pharmaceutical companies to transform promising research insights into viable drug candidates. The company's financial sustenance is woven into its intricate business model, which revolves around the development and commercialization of therapeutic antibodies. Their flagship product, efgartigimod, has made significant strides in treating autoimmune diseases such as generalized myasthenia gravis, showcasing the company's ability to translate its scientific endeavors into substantial revenue streams. Argenx generates income primarily through product sales, milestone payments, and royalties from collaborative partnerships. As the company continues to advance its pipeline and expand its global presence, it demonstrates a robust commitment to addressing unmet medical needs while maintaining a keen eye on sustainable growth and profitability. This delicate balance of innovation and financial acumen allows argenx to reinforce its position in the competitive biotech industry.
